DiaGenic ASA (DiaGenic) is a life sciences company principally engaged in the research, development and sale of modern and user friendly diagnostic tests, which help in early diagnosis of devastating diseases. The company makes use of its patented method which uses the identification of disease-specific gene signatures from easily available sample material such as blood. DiaGenic`s first two tests for the early detection of breast cancer and Alzheimer`s disease are on track to enter extensive clinical trials. The company is headquartered in Oslo, Norway.The company reported revenue of (Norwegian Krone) NOK 0.00 during the fiscal year ended 2008, whereas the company reported revenues of NOK 0.06 million during the fiscal year ended 2007. The operating loss of the company was NOK 36.38 million during the fiscal year 2008, as compared to an operating loss of NOK 29.02 million during 2007. The net loss of the company was NOK 34.58 million during the fiscal year 2008, as compared to a net loss of NOK 28.13 million during 2007.